In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
The CRL-1621cell line is reported to be positive for Epstein-Barr nuclear antigen (EBNA +) and Epstein-Barr viral capsid antigen (EBVCA +). Since the HMy2.CIR cell line was derived from the HMy.2 B lymphoblastoid cell line, a fast growing mutant of the ARH-77 cell line (ATCC CRL-1621), it is assumed to be EBNA positive.
The HMy2.CIR cell line was derived from the HMy.2 B lymphoblastoid cell line, a fast growing mutant of the ARH-77 cell line (ATCC CRL-1621), by gamma irradiation and selection for loss of HLA class I antigen expression. [23312]
The cells express no HLA A or B locus products, but do express small amounts of HLA Cw4.
The cells are useful as host for transfected class I major histocompatibility antigen genes.
ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C
Subculturing:
Protocol: Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10(5) viable cells/ml. Interval: Maintain between 2 X 10(5) and 1 X 10(6) viable cells/ml. Medium Renewal: Every 2 to 3 days
Preservation:
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase
23312: Storkus WJ, et al. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc. Natl. Acad. Sci. USA 86: 2361-2364, 1989. PubMed: 2784569
